{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:37:31Z","timestamp":1792427851009,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The first-line treatment for persistent, recurrent, or metastatic cervical cancer continues to pose significant clinical challenges. While the application of immune checkpoint inhibitors (ICIs) has transformed the existing treatment paradigm, the lack of direct comparisons between the different immunotherapy regimens limits the selection of optimal strategies for diverse patient populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We have searched through the PubMed, Embase, and Web of Science databases for phase III randomized controlled trials (RCTs) for persistent, recurrent, or metastatic cervical cancer. The primary endpoints were overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of grade \u22653 treatment-related adverse events (TRAEs) were the secondary endpoints. Data were analyzed using a frequentist network meta-analysis and Bucher\u2019s indirect comparison method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four phase III RCTs (1,924 patients) were enrolled. Combinations with bevacizumab, pembrolizumab, and atezolizumab demonstrated comparable efficacy to each other [OS relative hazard ratio (HR) = 1.11, 95%CI = 0.77\u20131.62; PFS relative HR = 1.09, 95%CI = 0.78\u20131.52), both significantly superior to chemotherapy. In the treatment setting without bevacizumab, cadonilimab outperformed pembrolizumab plus chemotherapy for OS (relative HR = 0.75, 95%CI = 0.45\u20131.25) and PFS (relative HR = 0.64, 95%CI = 0.40\u20131.03). Patients with programmed death-ligand 1 (PD-L1)-positive tumors [combined positive score (CPS) \u2265 1] derived clear benefit from immunotherapy, whereas the PD-L1-negative (CPS &amp;lt; 1) populations experienced limited improvements overall. However, cadonilimab showed a trend toward PFS improvement in this subgroup (HR = 0.65, 95%CI = 0.42\u20131.03,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.06) and reached significance for PFS in the metastatic subgroup (HR = 0.70, 95%CI = 0.54\u20130.92,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05). The ORR evaluation confirmed that all the combinations with ICIs greatly increased the tumor response rate. In addition, the risk of grade \u22653 TRAEs was comparable between the pembrolizumab and cadonilimab regimens (OR = 1.07, 95%CI = 0.57\u20132.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the bevacizumab combination setting, pembrolizumab and atezolizumab demonstrate equivalent efficacy. Cadonilimab excels in settings without bevacizumab, showing efficacy in PD-L1-negative patients and metastatic subgroups. Thus, clinical decision-making should integrate multiple pieces of information such as the PD-L1 expression status and bevacizumab eligibility, and individual safety profiles should be considered to create personalized treatment routes. In the future, head-to-head comparative studies are urgently needed to precisely identify optimal treatment regimens for certain types of patient subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251158152<\/jats:ext-link>\n                      , identifier CRD420251158152.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1789532","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:26:09Z","timestamp":1776317169000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoge","family":"Wang","sequence":"first","affiliation":[{"name":"College of Pharmacy, Zhejiang University of Technology","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Zhejiang University of Technology","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojun","family":"Wang","sequence":"additional","affiliation":[{"name":"Hangzhou Aeronautical Sanatorium for Special Service of Chinese Air Force","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Zhejiang University of Technology","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimeng","family":"Huang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Zhejiang University of Technology","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Sun","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Zhejiang University of Technology","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2025.04.006","article-title":"Recent advances in cervical cancer treatment: Innovations from early-stage to advanced disease","volume":"64","author":"Lin","year":"2025","journal-title":"Taiwanese J Obstet Gynecol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00977-w","article-title":"Treatment advances across the cervical cancer spectrum","volume":"22","author":"Francoeur","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase ii keynote-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: Final analysis according to bevacizumab use in the randomized keynote-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.037","article-title":"Beatcc (Engot-Cx10\/Geico 68-C\/Jgog-1084\/Gog-3030): A randomized phase iii trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage ivb), persistent, or recurrent cervical cancer","volume":"190","author":"Oaknin","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (Compassion-16): A randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.3802\/jgo.2024.35.e77","article-title":"Ql1604 plus paclitaxel-cisplatin\/ carboplatin in patients with recurrent or metastatic cervical cancer: An open-label, single-arm, phase ii trial","volume":"35","author":"Fang","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103308","article-title":"A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer","volume":"85","author":"Wen","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104357","article-title":"Association of pd-l1 expression with survival benefit from pd-1\/pd-l1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase iii randomized clinical trials","volume":"198","author":"Kuang","year":"2024","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The prisma statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clin Res Ed)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of keynote-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses from the keynote-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.3802\/jgo.2025.36.e110","article-title":"Pembrolizumab plus chemotherapy with or without bevacizumab in east asian participants with persistent, recurrent, or metastatic cervical cancer: Results from keynote-826 final analysis","volume":"36","author":"Kim","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (Beatcc): A randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1200\/jco.2025.43.16_suppl.5509","article-title":"Cadonilimab plus platinum-based chemotherapy 6 bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of compassion-16","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: Causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1789532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:26:10Z","timestamp":1776317170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1789532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1789532"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1789532","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"1789532"}}